SK Bioscience Co (XKRX:302440) Accounts Payable & Accrued Expense : ₩25,887 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is SK Bioscience Co Accounts Payable & Accrued Expense?

SK Bioscience Co's quarterly accounts payable & accrued expense declined from Jun. 2023 (₩21,619 Mil) to Sep. 2023 (₩20,644 Mil) but then increased from Sep. 2023 (₩20,644 Mil) to Dec. 2023 (₩25,887 Mil).

SK Bioscience Co's annual accounts payable & accrued expense declined from Dec. 2021 (₩177,349 Mil) to Dec. 2022 (₩45,679 Mil) and declined from Dec. 2022 (₩45,679 Mil) to Dec. 2023 (₩25,887 Mil).

SK Bioscience Co Accounts Payable & Accrued Expense Historical Data

The historical data trend for SK Bioscience Co's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SK Bioscience Co Accounts Payable & Accrued Expense Chart

SK Bioscience Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

24,596.73

50,064.54

177,348.91

45,678.70

25,886.95

SK Bioscience Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															45,678.70	28,208.25	21,618.93	20,643.53	25,886.95

SK Bioscience Co Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

SK Bioscience Co (XKRX:302440) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SK Bioscience Co Ltd (XKRX:302440) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

310, Pangyo-ro, Bundang-gu, Gyeonggi-do, Seongnam-si, KOR, 13494

Website

https://www.skbioscience.co.kr

SK Bioscience Co Ltd is a South Korean pharmaceutical company. It is engaged in the manufacturing and developing of vaccine. The company has registered SKYCellflu prefilled syringe (PFS), the first cell culture influenza vaccine in Korea, followed by the licensure of SKYCellflu Quadrivalent prefilled syringe and 13-valent Pneumococcal Conjugate Vaccine. Further it has several other vaccines under development and clinical trials including recombinant rotavirus vaccine. In addition, the development of new typhoid conjugate vaccine and innovative pneumococcal vaccine is ongoing in collaboration with external partners.

SK Bioscience Co (XKRX:302440) Headlines

No Headlines